Gallic acid reduces the amount of EGFR via speeding up EGFR transformation, causing death in EGFR mutant non-small cell lung cancer cells (MSCLC), although proteasome antagonists can counteract this action [118]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.